Logo image of CARM

CARISMA THERAPEUTICS INC (CARM) Stock Fundamental Analysis

NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD

0.388  -0.01 (-1.62%)

After market: 0.3879 0 (-0.03%)

Fundamental Rating

1

Taking everything into account, CARM scores 1 out of 10 in our fundamental rating. CARM was compared to 556 industry peers in the Biotechnology industry. CARM has a bad profitability rating. Also its financial health evaluation is rather negative. CARM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CARM has reported negative net income.
In the past year CARM has reported a negative cash flow from operations.
CARM had negative earnings in each of the past 5 years.
CARM had negative operating cash flow in 4 of the past 5 years.
CARM Yearly Net Income VS EBIT VS OCF VS FCFCARM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of CARM (-318.22%) is worse than 93.53% of its industry peers.
Industry RankSector Rank
ROA -318.22%
ROE N/A
ROIC N/A
ROA(3y)-102.03%
ROA(5y)-64.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARM Yearly ROA, ROE, ROICCARM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CARM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARM Yearly Profit, Operating, Gross MarginsCARM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

CARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CARM has more shares outstanding
The number of shares outstanding for CARM has been increased compared to 5 years ago.
CARM has a worse debt/assets ratio than last year.
CARM Yearly Shares OutstandingCARM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CARM Yearly Total Debt VS Total AssetsCARM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -36.68, we must say that CARM is in the distress zone and has some risk of bankruptcy.
CARM's Altman-Z score of -36.68 is on the low side compared to the rest of the industry. CARM is outperformed by 90.83% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -36.68
ROIC/WACCN/A
WACC10.34%
CARM Yearly LT Debt VS Equity VS FCFCARM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.34 indicates that CARM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.34, CARM is not doing good in the industry: 83.45% of the companies in the same industry are doing better.
CARM has a Quick Ratio of 1.34. This is a normal value and indicates that CARM is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.34, CARM is not doing good in the industry: 82.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.34
CARM Yearly Current Assets VS Current LiabilitesCARM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

CARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.00%, which is quite impressive.
Looking at the last year, CARM shows a very strong growth in Revenue. The Revenue has grown by 32.42%.
CARM shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -9.56% yearly.
EPS 1Y (TTM)39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
Revenue 1Y (TTM)32.42%
Revenue growth 3Y-9.56%
Revenue growth 5YN/A
Sales Q2Q%9.77%

3.2 Future

CARM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.26% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y54.94%
EPS Next 2Y24.05%
EPS Next 3Y17.34%
EPS Next 5Y10.26%
Revenue Next Year-18.24%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CARM Yearly Revenue VS EstimatesCARM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 0 0 0 0 0
CARM Yearly EPS VS EstimatesCARM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CARM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CARM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARM Price Earnings VS Forward Price EarningsCARM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARM Per share dataCARM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CARM's earnings are expected to grow with 17.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.05%
EPS Next 3Y17.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CARM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARISMA THERAPEUTICS INC

NASDAQ:CARM (7/25/2025, 8:00:01 PM)

After market: 0.3879 0 (-0.03%)

0.388

-0.01 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners31.76%
Inst Owner Change0.27%
Ins Owners1.19%
Ins Owner Change0%
Market Cap16.21M
Analysts80
Price Target1.02 (162.89%)
Short Float %3.48%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-116.57%
Min EPS beat(2)-153.39%
Max EPS beat(2)-79.74%
EPS beat(4)1
Avg EPS beat(4)-59.75%
Min EPS beat(4)-153.39%
Max EPS beat(4)11.02%
EPS beat(8)4
Avg EPS beat(8)-25.91%
EPS beat(12)6
Avg EPS beat(12)-4.47%
EPS beat(16)9
Avg EPS beat(16)41.99%
Revenue beat(2)0
Avg Revenue beat(2)-18.21%
Min Revenue beat(2)-33.92%
Max Revenue beat(2)-2.51%
Revenue beat(4)1
Avg Revenue beat(4)13.49%
Min Revenue beat(4)-39.29%
Max Revenue beat(4)129.7%
Revenue beat(8)4
Avg Revenue beat(8)64.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-84.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)-29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0.48
BVpS-0.88
TBVpS-0.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -318.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-102.03%
ROA(5y)-64.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.57%
Cap/Sales 0.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.34
Quick Ratio 1.34
Altman-Z -36.68
F-Score4
WACC10.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
EPS Next Y54.94%
EPS Next 2Y24.05%
EPS Next 3Y17.34%
EPS Next 5Y10.26%
Revenue 1Y (TTM)32.42%
Revenue growth 3Y-9.56%
Revenue growth 5YN/A
Sales Q2Q%9.77%
Revenue Next Year-18.24%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y39.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-501.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-511.3%
OCF growth 3YN/A
OCF growth 5YN/A